We are live on
!
Find out more
SM
Sabby Management Portfolio holdings
AUM
$111M
1-Year Est. Return
74.4%
This Fund
S&P 500
This Quarter
Est. Return
-3.19%
1 Year Est. Return
-74.4%
3 Year Est. Return
-95.55%
5 Year Est. Return
-99.44%
10 Year Est. Return
-99.5%
AUM
$522M
AUM Growth
-$148M
(-22%)
Cap. Flow
+$274K
Cap. Flow
% of AUM
0.05%
Top 10 Holdings %
Top 10 Hldgs %
68.85%
Holding
172
New
42
Increased
30
Reduced
27
Closed
64
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Biogen
BIIB
|
+$18.7M |
| 2 |
AstraZeneca
AZN
|
+$11.5M |
| 3 |
XWELL
XWEL
|
+$3.81M |
| 4 |
RVPH
REVIVA PHARMA HLDGS INC
RVPH
|
+$3.63M |
| 5 |
CEL-SCI Corp
CVM
|
+$2.66M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
SRNE
Sorrento Therapeutics, Inc.
SRNE
|
+$4.87M |
| 2 |
IMMU
Immunomedics Inc
IMMU
|
+$4.25M |
| 3 |
Acadia Pharmaceuticals
ACAD
|
+$4.12M |
| 4 |
SPI
SPI Energy Co., Ltd. Ordinary Shares
SPI
|
+$3.57M |
| 5 |
Rockwell Medical
RMTI
|
+$3.04M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 80.62% |
| 2 | Healthcare | 18.22% |
| 3 | Industrials | 0.71% |
| 4 | Technology | 0.22% |
| 5 | Consumer Discretionary | 0.14% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
CALL
Biogen
BIIB
$31.9B
| $67.6M | 12.96% |
2,762
-592
| -18% | -$153K |
|
|
2
PUT
Biogen
BIIB
$31.9B
| $49.6M | 9.5% |
2,024
-335
| -14% | -$86.4K |
|
3
CALL
SPDR Gold Trust
GLD
$145B
| $40.7M | 7.8% |
2,282
+20
| +0.9% | +$3.52K |
|
4
PUT
Moderna
MRNA
$57.4B
| $39.1M | 7.49% |
3,740
-432
| -10% | -$43.7K |
|
5
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$799B
| $37.4M | 7.17% |
1,000
+69
| +7% | +$24.5K |
|
6
PUT
iShares S&P 100 ETF
OEF
$20.1B
| $32.1M | 6.16% |
1,638
-1,473
| -47% | -$241K |
|
|
7
Biogen
BIIB
$31.9B
| $28.6M | 5.49% |
116,970
+72,434
| +163% | +$18.7M |
|
8
PUT
State Street SPDR NYSE Technology ETF
XNTK
$1.87B
| $28.4M | 5.44% |
2,017
+680
| +51% | +$87.2K |
|
|
9
AstraZeneca
AZN
$251B
| $18.2M | 3.5% |
182,500
+108,527
| +147% | +$11.5M |
|
|
10
PUT
AstraZeneca
AZN
$251B
| $17.5M | 3.35% |
1,746
+208
| +14% | +$22K |
|
|
11
Moderna
MRNA
$57.4B
| $12.1M | 2.32% |
116,000
-5,975
| -5% | -$604K |
|
|
12
CALL
iShares S&P 100 ETF
OEF
$20.1B
| $9M | 1.73% |
459
-780
| -63% | -$127K |
|
|
13
CALL
Moderna
MRNA
$57.4B
| $7.48M | 1.43% |
716
-376
| -34% | -$38K |
|
|
KNDI
14
PUT
Kandi Technologies Group
KNDI
$58.7M
| $7.04M | 1.35% |
+10,203
| New | +$84K |
|
15
PUT
Zoom
ZM
$27.2B
| $6.75M | 1.29% |
+200
| New | +$89.2K |
|
|
CVM.WS
16
PUT
DELISTED
Cel-Sci Corp Series S
CVM.WS
| $6.42M | 1.23% |
5,503
-2,270
| -29% | -$2.65M |
|
17
PUT
PENN Entertainment
PENN
$2.38B
| $6.31M | 1.21% |
+731
| New | +$52.2K |
|
|
JJT
18
CALL
DELISTED
iPath Series B Bloomberg Tin Subindex Total ReturnSM ETN
JJT
| $6.26M | 1.2% |
3,726
+1,750
| +89% | +$85.9K |
|
|
SRNE
19
PUT
DELISTED
Sorrento Therapeutics, Inc.
SRNE
| $6.25M | 1.2% |
9,164
+2,021
| +28% | +$16.2K |
|
20
PUT
Cardiff Oncology
CRDF
$104M
| $5.16M | 0.99% |
2,870
-1,017
| -26% | -$17.9K |
|
|
21
CALL
Cardiff Oncology
CRDF
$104M
| $4.72M | 0.9% |
2,622
+2,305
| +727% | +$40.5K |
|
22
PUT
Peloton Interactive
PTON
$2.13B
| $4.55M | 0.87% |
+300
| New | +$36.5K |
|
|
AVEO
23
PUT
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
| $4.31M | 0.83% |
7,471
+670
| +10% | +$3.84K |
|
|
SRNE
24
CALL
DELISTED
Sorrento Therapeutics, Inc.
SRNE
| $4.27M | 0.82% |
+6,262
| New | +$50.3K |
|
|
25
XWELL
XWEL
$7.73M
| $3.99M | 0.77% |
167,748
+108,186
| +182% | +$3.81M |
|
Similar funds
IWA
BFA
WPWM
BCM
ZS
KC
FI
CIM
Sabby Management's Q4 2020 Portfolio in Review
As of Q4 2020, Sabby Management held 172 positions worth $522M, down 22% from $670M the previous quarter. Its ten largest holdings account for 69% of the portfolio.
Sabby Management's Q4 2020 filing shows 42 new, 30 increased, 27 reduced and 64 closed positions. Its largest new stake was REVIVA PHARMA HLDGS INC: 17,915 shares worth $3.13M. The largest sale was Sorrento Therapeutics, Inc., an estimated $4.87M.
By sector, the portfolio is most concentrated in Miscellaneous at 81% of assets, down from 84% a quarter earlier, followed by Healthcare and Industrials.
- Sabby Management's largest Q4 2020 buy was REVIVA PHARMA HLDGS INC: 17,915 shares worth $3.13M.
- Sabby Management added most to Biogen in Q4 2020, an estimated $18.7M increase.
- Sabby Management's biggest Q4 2020 reduction was Rockwell Medical, cutting an estimated $3.04M.
- Sabby Management fully exited Sorrento Therapeutics, Inc. in Q4 2020, selling an estimated $4.87M.
- Sabby Management's ten largest holdings make up 69% of its $522M portfolio in Q4 2020.
- Sabby Management opened 42 new positions and closed 64 in Q4 2020.
- Sabby Management's portfolio value fell 22% quarter-over-quarter to $522M.
Based on Sabby Management's 13F filing for Q4 2020, filed 16 Feb 2021.